In addition to spending time catching up with fellow patients and caregivers and attending the myriad of useful workshops featured at Life Fest 2014, participants were treated to an update of what is new in [...]
An article in Wayne Patch, a community-specific news, information and engagement network, features Life Fest 2014, The Life Raft Group’s biennial convention which was held on November 7-9 in Teaneck, New Jersey. In the article, [...]
By Dr. Anette Duensing, University of Pittsburgh Cancer Institute, and Dr. Maria Debiec-Rychter, KU Leuven, Belgium, LRG Research Team Dr. Maria Debiec-Rychter Dr. Anette Duensing Although most GISTs initially respond well [...]
The time it takes between the appearance of first symptoms of a rare disease and when the correct diagnosis is given, is often years if not decades instead of days or weeks like it is [...]
The Life Raft Group is pleased to announce the release of the third issue of The GIST Cancer Journal, the official journal of the Life Raft Group and the first academic journal devoted solely to [...]
In December, 2013, the Life Raft Group launched its “We Are the Cure” campaign to fund GIST research in response to the shrinking pool of available funds. As a rare disease, GIST research is impacted more than other more common cancers like breast and colon. Institutions like the National Cancer Institute are funding just four to five percent of all research proposals which means that a rare cancer like GIST is lost amongst the roughly 200 cancers competing for funding.
Mo Collins is not your typical actress/comedienne, because Mo Collins is a GIST survivor. Keep reading to learn more about Mo Collins and her fight against GIST. Mo is using this gift in a very selfless way by organizing a comedy fundraiser for the Life Raft Group and GIST research.
Drs. Jonathan Fletcher, of Brigham & Women’s Hospital, Harvard University and Maria Debiec-Rychter, of the Catholic University in Leuven, Belgium, members of the LRG Research Team were part of a recently published study that looked at the effectiveness of GDC-0941, a PI3K inhibitor when used in combination with imatinib (Gleevec).
By Drs. Sebastian Bauer, West German Cancer Center, University of Essen, Germany and Jonathan Fletcher, Brigham & Women’s Hospital, Harvard University, LRG Research Team Researchers talk plainly about microGISTs, how this cancer develops and what all [...]
